Cargando…

How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study

Orodispersible tablets (ODTs) offer rapid disintegration of the dosage form when placed on the tongue, which leads to fast release of the active pharmaceutical ingredient. Despite increased use in diverse patient populations, there have been numerous challenges associated with ODTs. One such concern...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Neel, Redfearn, Andrew, MacLeod, Graeme, Tuleu, Catherine, Hanson, Ben, Orlu, Mine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408023/
https://www.ncbi.nlm.nih.gov/pubmed/32660030
http://dx.doi.org/10.3390/pharmaceutics12070651
_version_ 1783567741379149824
author Desai, Neel
Redfearn, Andrew
MacLeod, Graeme
Tuleu, Catherine
Hanson, Ben
Orlu, Mine
author_facet Desai, Neel
Redfearn, Andrew
MacLeod, Graeme
Tuleu, Catherine
Hanson, Ben
Orlu, Mine
author_sort Desai, Neel
collection PubMed
description Orodispersible tablets (ODTs) offer rapid disintegration of the dosage form when placed on the tongue, which leads to fast release of the active pharmaceutical ingredient. Despite increased use in diverse patient populations, there have been numerous challenges associated with ODTs. One such concern is the lack of standardised assessment of disintegration behaviour. In the European Pharmacopoeia, ‘orodispersibles’ are defined as such if disintegration time is faster than 3 min. Common in vitro measurement methods only provide single time point data and have limited physiological accuracy. To determine more bio-predictive disintegration kinetics, a bench-top in vitro oral cavity model (OCM) was modified and piloted to assess disintegration of three ODTs of differing hardness. All ODTs disintegrated similarly within the OCM—surface breakdown/swelling, initial ‘wash away’ and final ‘wash away’. The distinct advantage presented within this pilot study using the OCM is the opportunity to ascertain disintegration behaviour profiles of ODTs by evaluating changes in the observable area during simulated oral processing. The model could be implemented as a decision-support tool during the early stages of the drug design process to improve acceptability and further understand ODT disintegration behaviour.
format Online
Article
Text
id pubmed-7408023
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74080232020-08-12 How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study Desai, Neel Redfearn, Andrew MacLeod, Graeme Tuleu, Catherine Hanson, Ben Orlu, Mine Pharmaceutics Article Orodispersible tablets (ODTs) offer rapid disintegration of the dosage form when placed on the tongue, which leads to fast release of the active pharmaceutical ingredient. Despite increased use in diverse patient populations, there have been numerous challenges associated with ODTs. One such concern is the lack of standardised assessment of disintegration behaviour. In the European Pharmacopoeia, ‘orodispersibles’ are defined as such if disintegration time is faster than 3 min. Common in vitro measurement methods only provide single time point data and have limited physiological accuracy. To determine more bio-predictive disintegration kinetics, a bench-top in vitro oral cavity model (OCM) was modified and piloted to assess disintegration of three ODTs of differing hardness. All ODTs disintegrated similarly within the OCM—surface breakdown/swelling, initial ‘wash away’ and final ‘wash away’. The distinct advantage presented within this pilot study using the OCM is the opportunity to ascertain disintegration behaviour profiles of ODTs by evaluating changes in the observable area during simulated oral processing. The model could be implemented as a decision-support tool during the early stages of the drug design process to improve acceptability and further understand ODT disintegration behaviour. MDPI 2020-07-09 /pmc/articles/PMC7408023/ /pubmed/32660030 http://dx.doi.org/10.3390/pharmaceutics12070651 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Desai, Neel
Redfearn, Andrew
MacLeod, Graeme
Tuleu, Catherine
Hanson, Ben
Orlu, Mine
How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title_full How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title_fullStr How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title_full_unstemmed How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title_short How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study
title_sort how do orodispersible tablets behave in an in vitro oral cavity model: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408023/
https://www.ncbi.nlm.nih.gov/pubmed/32660030
http://dx.doi.org/10.3390/pharmaceutics12070651
work_keys_str_mv AT desaineel howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy
AT redfearnandrew howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy
AT macleodgraeme howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy
AT tuleucatherine howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy
AT hansonben howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy
AT orlumine howdoorodispersibletabletsbehaveinaninvitrooralcavitymodelapilotstudy